1. Home
  2. BVS vs CLLS Comparison

BVS vs CLLS Comparison

Compare BVS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bioventus Inc.

BVS

Bioventus Inc.

HOLD

Current Price

$7.40

Market Cap

508.4M

Sector

Health Care

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.71

Market Cap

485.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVS
CLLS
Founded
2011
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
508.4M
485.6M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
BVS
CLLS
Price
$7.40
$4.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$13.50
$8.50
AVG Volume (30 Days)
277.3K
112.6K
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$563,829,000.00
$82,551,000.00
Revenue This Year
N/A
$32.58
Revenue Next Year
$7.11
$20.68
P/E Ratio
$48.57
N/A
Revenue Growth
1.58
129.04
52 Week Low
$5.81
$1.10
52 Week High
$11.25
$5.48

Technical Indicators

Market Signals
Indicator
BVS
CLLS
Relative Strength Index (RSI) 50.09 54.48
Support Level $7.26 $4.47
Resistance Level $7.71 $5.03
Average True Range (ATR) 0.26 0.28
MACD -0.02 -0.02
Stochastic Oscillator 44.75 54.55

Price Performance

Historical Comparison
BVS
CLLS

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: